Alpine Woods Capital Investors’s Celgene Corp CELG Stock Holding History

Alpine Woods Capital Investors’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,500	Closed	-$758K	–	416
2018 Q1	$758K	Hold	8,500	–	–	0.04%	269
2017 Q4	$887K	Hold	8,500	–	–	0.04%	263
2017 Q3	$1.24M	Hold	8,500	–	–	0.06%	234
2017 Q2	$1.1M	Buy	+8,500	New	+$1.04M	0.06%	235

Other funds holding CELG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alpine Woods Capital Investors's CELG Position: Q2 2018 in Review

Alpine Woods Capital Investors sold out of Celgene Corp (CELG) in Q2 2018, closing a stake of 8,500 shares — an estimated $758K sold.

Alpine Woods Capital Investors first reported a position in CELG in Q2 2017 and held it in 4 quarters. The position peaked at $1.24M in Q3 2017. 1,360 funds tracked by Wall St. Rank hold CELG as of Q2 2018.

Alpine Woods Capital Investors reported no remaining Celgene Corp position as of Q2 2018 after selling out during the quarter.
Alpine Woods Capital Investors sold 8,500 Celgene Corp shares in Q2 2018, an estimated $758K.
Alpine Woods Capital Investors first reported a position in Celgene Corp in Q2 2017 and held it in 4 quarters.
Alpine Woods Capital Investors's Celgene Corp position peaked at $1.24M in Q3 2017.
1,360 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2018.

Based on Alpine Woods Capital Investors's 13F filing for Q2 2018, filed 9 Aug 2018.